BioPharma Resources

Drug Trial Radar · NCT05552222

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,590 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,590

Planned (sponsor's estimate)

Start

Oct 25, 2022

Primary completion

Apr 30, 2031

Study completion Oct 28, 2033

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Conditions

  • Multiple Myeloma

Interventions

  • TeclistamabDrug

    Teclistamab will be administered as SC injection.

  • DaratumumabDrug

    Daratumumab will be administered as SC injection.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • DexamethasoneDrug

    Dexamethasone will be administered either orally or intravenously (IV).

  • TalquetamabDrug

    Talquetamab will be administered as SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From randomization to the date of disease progression or death (Up to 09 years)
  2. 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)Time frame: At Month 12

Locations

270 sites in 25 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • UCSF Fresno

    Clovis, California · Recruiting

  • City of Hope Duarte

    Duarte, California · Recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • University of Connecticut

    Farmington, Connecticut · Recruiting

  • Yale New Haven Hospital

    New Haven, Connecticut · Recruiting

  • ChristianaCare Helen F Graham Cancer Center and Research Institute

    Newark, Delaware · Recruiting

  • Memorial Healthcare System

    Hollywood, Florida · Recruiting

  • AdventHealth Medical Group Blood & Marrow Transplant at Orlando

    Orlando, Florida · Recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Recruiting

  • City of Hope Cancer Center

    Newnan, Georgia · Recruiting

  • University Of Illinois Medical Center

    Chicago, Illinois · Recruiting

  • Loyola University Medical Center

    Maywood, Illinois · Recruiting

  • University of Iowa Health Care

    Waukee, Iowa · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • LSUHSC Shreveport Feist-Weiller Cancer Center

    Shreveport, Louisiana · Recruiting

  • Johns Hopkins University School of Medicine JHUSOM

    Baltimore, Maryland · Recruiting

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion

    Detroit, Michigan · Recruiting

  • Cancer And Hematology Centers of Western Michigan PC

    Grand Rapids, Michigan · Recruiting

  • Henry Ford Providence Novi Hospital

    Novi, Michigan · Recruiting

  • Henry Ford Providence Southfield CK Potluri Cancer Center

    Southfield, Michigan · Recruiting

  • MidAmerica Cancer Care

    Kansas City, Missouri · Completed

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Christus St. Vincent Regional Cancer Center

    Santa Fe, New Mexico · Recruiting

  • Hematology-Oncology Associates of CNY

    East Syracuse, New York · Recruiting

  • Northwell Health Cancer Institute

    Lake Success, New York · Recruiting

  • NYU Langone Hospital Long Island

    Mineola, New York · Recruiting

  • Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Weill Cornell Medical College

    New York, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Novant Health

    Charlotte, North Carolina · Recruiting

Showing 40 of 270 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.